Compare Ginkgo Bioworks Holdings Inc (DNA) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Freshworks Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Freshworks Inc trades at $10.5 (market cap $2.89B). The key difference: Freshworks Inc is far larger — about 4.9× Ginkgo Bioworks Holdings Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | FRSH | |
|---|---|---|
Market Cap | $590.53M | $2.89B |
Sector | Health | Technology |
52-Week High | $16.14 | $14.77 |
52-Week Low | $5.48 | $6.88 |
Enterprise Value | $627.78M | $2.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Freshworks (FRSH) trades at $10.83, up 4.54% today, with a bullish technical signal from moving averages. The company shows strong fundamental improvement, with revenue growing from $498M in 2022 to $839M in 2025 and achieving profitability with a net income margin of 20.69%. Recent news highlights AI product launches and a strategic pivot to employee experience, with Q2 2026 earnings due August 4, 2026.
The outlook is positive given consistent revenue growth, high gross margins, and analyst consensus pointing to a 26% upside. Risks include execution of the new strategic focus and competitive pressures in the SaaS sector. The stock presents a value opportunity with a P/E of 17.63, below software industry averages, supported by improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
